Filtered By:
Condition: Guillain-Barr Syndrome
Countries: USA Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 23 results found since Jan 2013.
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guillain-Barre syndrome in Mexico: clinical features and validation of Brighton Collaboration Group criteria
CONCLUSION: GBS is a frequent autoimmune neuropathy that has been associated with preceding infections and with vaccination campaigns. For SARS-CoV-2 vaccination campaign in Mexico, validation of Brighton Criteria is necessary. Although Mexico's GBS epidemiology has been changing throughout recent years, this study provides similar data compared to other countries.PMID:35383873 | DOI:10.33588/rn.7408.2021437
Source: Revista de Neurologia - April 6, 2022 Category: Neurology Authors: J C L ópez-Hernández J A Galnares-Olalde A Guti érrez S A Estrada M Garc ía-Grimshaw E S Vargas-Ca ñas Source Type: research
